Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT02341560 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

732

Enrollment

INDUSTRY

Sponsor class

Stopped An interim analysis did not warrant to continue enrollment

Conditions

Non Arteritic Anterior Ischemic Optic Neuropathy

Interventions

DRUG: QPI-1007 Injection - 1.5 mg
DRUG: QPI-1007 Injection - 3.0 mg
OTHER: Sham Injection Procedure

Sponsor

Quark Pharmaceuticals